Form 4: Enanta CMO Granted 110,000 Stock Options

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, was granted 110,000 stock options with an exercise price of $13.66, vesting over four years.

Summary

• Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc. (ENTA), was granted 110,000 stock options.
• The transaction date for this grant was November 25, 2025.
• Each stock option grants the right to buy one share of common stock.
• The exercise price for these options is $13.66 per share.
• The options will vest quarterly in substantially equal installments over four years from the grant date, subject to continued employment.
• The expiration date for these stock options is November 25, 2035.
• Following this transaction, Mr. Rottinghaus beneficially owns 110,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant). While positive for management alignment, it is a standard disclosure and does not inherently indicate significant operational or financial news, hence a neutral-to-slightly positive score.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice to attract and retain key executive talent in the biotechnology sector.

Negatives

• The exercise of these options in the future could lead to a dilution of existing shareholders' equity, although this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is contingent on the company's stock price exceeding the exercise price of $13.66; if the stock price remains below this, the options may not be 'in the money'.
• The options are subject to a four-year vesting schedule, and forfeiture would occur if the optionholder's employment ceases before full vesting.

Future Outlook

The stock option grant indicates a long-term incentive for the Chief Medical Officer, suggesting an expectation of continued contribution and alignment with the company's future growth and success over the next four years.

Industry Context

Equity grants, particularly stock options with vesting schedules, are a common component of executive compensation packages in the biotechnology and pharmaceutical industries. They are designed to incentivize long-term performance and retention of key scientific and medical leadership.

Comparison to Industry Standards

• The grant of stock options to a Chief Medical Officer is a standard compensation practice within the biotechnology and pharmaceutical sectors, comparable to similar roles at companies like Moderna, Pfizer, or Gilead Sciences, which frequently use equity to attract and retain top talent.
• The four-year vesting schedule is typical for executive equity awards, aligning with industry benchmarks for long-term incentive plans.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options, but also benefit from increased alignment of executive interests with long-term stock performance.
• Employees: The grant to a key executive may signal stability in leadership and a commitment to retaining top talent.

Next Steps

• The stock options will begin vesting quarterly over the next four years, subject to the Chief Medical Officer's continued employment.
• The Chief Medical Officer may choose to exercise vested options at any point before the expiration date of November 25, 2035, provided the stock price is favorable.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Chief Medical Officer, Scott T. Rottinghaus